Retrospective analysis on the efficacy of sunitinib/sorafenib in combination with dendritic cells-cytokine-induced killer in metastasis renal cell carcinoma after radical nephrectomy

• Published in: Journal of cancer research and therapeutics Vol. 14; no. 9; pp. 427 - 432
• Main Authors: Mai, Hai-Xing, Mei, Guo-Hui, Zhao, Fei-Long, Li, Bo-Tao, Tang, Yong-Yong, Zhang, Bin, Xu, Xiao-Jie, Chen, Li-Jun
• Format: Journal Article
• Language: English
• Published: India Wolters Kluwer India Pvt. Ltd 01.06.2018; Medknow Publications and Media Pvt. Ltd; Medknow Publications & Media Pvt. Ltd
• Subjects: Adult; Aged; Antigens; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Cancer; Cancer Vaccines; Carcinoma, Renal Cell - immunology; Carcinoma, Renal Cell - mortality; Carcinoma, Renal Cell - pathology; Carcinoma, Renal Cell - therapy; Combined Modality Therapy; Cytokine-Induced Killer Cells - immunology; Cytokine-Induced Killer Cells - metabolism; Cytokines; Cytotoxicity; Dendritic cells; Dendritic Cells - immunology; Dendritic Cells - metabolism; Diagnosis; Drug dosages; Female; Humans; Immunotherapy; Immunotherapy, Adoptive - methods; Indoles - administration & dosage; Kidney cancer; Kidney Neoplasms - immunology; Kidney Neoplasms - mortality; Kidney Neoplasms - pathology; Kidney Neoplasms - therapy; Lymphocytes; Male; Medical prognosis; Metastasis; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Nephrectomy; Niacinamide - administration & dosage; Niacinamide - analogs & derivatives; Phenylurea Compounds - administration & dosage; Postoperative Care; Pyrroles - administration & dosage; Renal cell carcinoma; Retrospective Studies; Sorafenib; Studies; Sunitinib; Survival Analysis; Targeted cancer therapy; Tomography; Treatment Outcome; Tumor necrosis factor-TNF; sunitinib; radical nephrectomy; sorafenib; dendritic cells-cytokine-induced killer; progression-free survival; 3-year overall survival; metastatic renal cell carcinoma
• ISSN: 0973-1482; 1998-4138
• DOI: 10.4103/0973-1482.180609

Objective: Sunitinib/sorafenib (SU/SO), dendritic cells (DCs), or DC-cytokine-induced killer (CIK) could significantly prolong progression-free survival (PFS), 3-year overall survival (OS), or 5-year OS for patients with metastatic renal cell carcinoma (mRCC). We retrospectively analyzed the clinical efficacy between SU/SO combined with DC-CIK and SU/SO monotherapy in treating renal cell carcinoma (RCC) patients with metastasis after radical nephrectomy. Materials and Methods: All patients (n = 34) with postoperative mRCC in our hospital from January 2009 to January 2014 were received either SU/SO monotherapy (Group 1, n = 15) or in combination with DC-CIK (Group 2, n = 19). A retrospective study was based on the primary endpoint (PFS) and secondary endpoint (OS). Results: At a median follow-up of 19.5 months, in Group 2, as compared with in Group 1, the median PFS was significantly longer (28.0 vs. 11.0 months, P = 0.03). Moreover, the 3-year OS was higher (57.1% vs. 28.6%). The cases of progressive diseases (PDs) and deaths were less in Group 2 than that in Group 1 (PD: 8 vs. 9, deaths: 3 vs. 5); however, the cases of stable diseases were more (11 vs. 6). In addition, the 3-year OS was higher in SU + DC-CIK group than that in SO + DC-CIK group (63.36% vs. 50%). There was no significant difference for PFS between SO + DC-CIK group and SU single agent group. Conclusions: SU/SO with DC-CIK could significantly prolong the median PFS, improve the 3-year OS rate, prolong the 3-year OS. It is likely to be a new approach for mRCC after radical nephrectomy.